NEW ORLEANS — In this Healio Video Perspective from the ARVO meeting, Diana V. Do, MD, discusses 48-week results from the phase 2/3 PHOTON trial.
The study evaluated the efficacy and safety of 8 mg of aflibercept in patients with diabetic macular edema.
“The PHOTON study provided some excellent data regarding the 8 mg dose of aflibercept administered every 12 or 16 weeks,” Do said. “The study met its primary endpoint, in that these higher doses of aflibercept provided extended duration of VEGF inhibition, which was clinically significant to these patients with diabetic